Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors - BeiGene Australia

Australia
- Australia
- Canada EN|FR
- China
- Germany
- Global
- Spain
- US

⟵ Back to Search Results

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Beigene Study ID

BGB-290-103

ClinicalTrials.gov ID

NCT03150810

EudraCT Number

2017-001553-14

Study Overview

Sex: All

Age: 18 Years to 99 Years (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years to 99 Years (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

You will be redirected to

Click the link above to continue or CANCEL